4-azidophenylpropionamide

Also Known As:

4-APP

Networked: 6 relevant articles (1 outcomes, 0 trials/studies)

1.	Dyslipidemias (Dyslipidemia) 01/01/2018 - "Although clinical investigation of LY2584702 has been terminated because of hepatotoxicity risk, we suggest that a selective inhibitor of p70 S6 serine/threonine protein kinase-1 with a larger margin of safety and without the possibility of being metabolized to 4-APP may be useful in the treatment of dyslipidemia."
2.	Poisoning 12/08/2000 - "While the strong inhibitory power of 4-APP on Shiga toxin 1 opens perspectives of therapeutic interventions, the ineffectiveness of the compound on ricin precludes its use as a suitable antidote in poisoning."
3.	Hypertrophy 10/01/1987 - "The prolonged administration of the hypocholesterolaemic drug 4-APP induced morphological changes in rat zona fasciculata cells (AER hypertrophy, peroxisome proliferation and lipid droplet depletion), enabling them to synthesise their own cholesterol and to maintain an adequate level of corticosterone output. "
4.	Hepatocellular Carcinoma (Hepatoma) 01/01/2017 - "In human hepatoma HepG2 cells, 4-APP, but not LY2584702, increased LDL uptake. "
5.	Fatty Liver 09/01/2002 - "Based on our data, we strongly suggested that pathogenesis of 4-APP induced-fatty liver may be due to uncontrolled free radical formation, peroxidation of lipids, and an associated lipid accumulation in the liver."